P-1100

Activity of Cefiderocol and Comparator Agents Against Global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2023)

IDWeek 2024 Los Angeles, CA **October 16–19, 2024**

Christopher Longshaw⁴, Miki Takemura¹, and Yoshinori Yamano¹

Motoyasu Onishi¹, Hidenori Yamashiro¹, Joshua M. Maher², Hank Kimbrough², Rodrigo Mendes², Boudewijn L.M. DeJonge³, Sean Nguyen³, ¹Shionogi & Co., Ltd., Osaka, Japan, ²Element Materials Technology, North Liberty, IA, USA, ³Shionogi Inc., NJ, USA, ⁴Shionogi B.V. London, UK

BACKGROUND

- Stenotrophomonas maltophilia is a ubiquitous multidrug-resistant opportunistic pathogen, for which limited treatment options are available.
- Infections caused by *S. maltophilia* have limited β-lactam treatment options due to the intrinsic resistant mechanisms such as the production of chromosomal L1 metallo-type carbapenemase and L2 extended-spectrum type β -lactamase.
- Cefiderocol (FDC) is a siderophore-conjugated cephalosporin with broad activity against Gramnegative bacteria, including S. maltophilia.

OBJECTIVE

• Determine susceptibility of FDC and comparator agents against *S* maltophilia clinical isolates, collected from the US and Europe in 2020-2023 as part of the SENTRY Antimicrobial Surveillance Program.

MATERIALS AND METHODS

- A total of 1,781 *S. maltophilia* isolates were consecutively collected from the US and Europe from 2020-2023. Minimum inhibitory concentrations (MICs) were determined according to Clinical and Laboratory Standards Institute (CLSI) broth microdilution methodology using cation-adjusted Mueller–Hinton broth (CAMHB) for comparator antimicrobial agents and iron-depleted CAMHB for FDC.
- Susceptibility was assessed according to CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) pharmacokinetic (PK)-pharmacodynamic (PD) breakpoints.

RESULTS

- The most common infection type from which isolates were collected was pneumonia (n=1,192), followed by bloodstream (n=208), skin and skin structure (n=166), urinary tract (n=56), and intra-abdominal infections (n=38) (Figure 1).
- Cumulative MIC distributions showed FDC was the most active agent against *S. maltophilia* with $MIC_{50/90}$ of 0.06/0.25 µg/mL (Figure 2, Table 1).
- MIC₉₀ values of levofloxacin (LVX), trimethoprim-sulfamethoxazole (SXT), and minocycline (MIN) were 4, 0.5, and 1 μ g/mL, respectively, and the MIC₉₀ values of remaining comparator agents were >8 μ g/mL (Figure 2, Table 1).
- 99.3, 83.1, 97.0, and 93.0% of the isolates were susceptible to FDC, LVX, SXT, and MIN respectively, according to CLSI breakpoints (Table 1).
- Against LVX-, SXT- or MIN-non-susceptible isolates, FDC retained activity (>98% susceptibility) according to both CLSI and EUCAST breakpoints, whereas the comparator agents were much less active (<90% susceptibility) (Table1).





Figure 2: Cumulative percentage distributions of cefiderocol and comparators MICs against *S* maltophilia (n=1,781)



Cefiderocol (FDC), levofloxacin (LVX), trimethoprim-sulfamethoxazole (SXT), minocycline (MIN), ceftazidime (CAZ), imipenem-relebactam (I/R), ceftazidime-avibactam (CZA)

Contact information: Motoyasu Onishi 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan Phone: +81-80-8537-0702 Email: motoyasu.oonishi@shionogi.co.jp




Table 1: Susceptibility of cefiderocol and comparator agents against S. maltophilia isolates collected from medical centers in the US and Europe during 2020-2023 MIC₉₀ MIC₅₀ **MIC range Isolate set** µg/mL **CLSI**^a **Antimicrobial agents** All (N=1,781) 0.25 FDC (n=1,781) 0.06 99.3 ≤0.004 - 8 LVX (n=1,779) ≤0.015 - >32 83.1 4 SXT (n=1,780) ≤0.125 ≤0.12 - >4 97.0 0.5 ≤0.06 - 16 93.0 MIN (n=1,780) 0.5 CAZ (n=1,779) 0.12 - >32 >32 >32 N/A 0.12 - >8 I/R (n=1,781) >8 >8 N/A 32 0.06 - >32 CZA (n=1,779) >32 N/A LVX NS^a (n=301) FDC (n=301) 0.06 0.25 99.7 ≤0.004 - 4 SXT (n=301) ≤0.12 - >4 0.25 88.7 0.12 - 16 65.6 MIN (n=301) SXT NS^a (n=53) FDC (n=53) 0.125 0.008 - 2 98.1 0.5 32 0.5 - > 32 35.8 LVX (n=53) 62.3 0.12 - 16 MIN (n=53) MIN NS^a (n=125) FDC (n=125) 0.06 0.25 0.008 - 1 99.7 LVX (n=125) 32 0.06 - >32 16.8

Non-susceptible (NS), susceptible (S), N/A (not applicable), cefiderocol (FDC), levofloxacin (LVX), trimethoprimsulfamethoxazole (SXT), minocycline (MIN), ceftazidime (CAZ), imipenem-relebactam (I/R), ceftazidimeavibactam (CZA), ^aFDC S \leq 1, LVX S \leq 2, SXT S \leq 2/38, MIN S \leq 1, breakpoints as published by CLSI (2024), ^bFDC S \leq 2, LVX S \leq 0.5, CAZ S \leq 4, I/R S \leq 2, CZA S \leq 8, PK-PD breakpoints as published by EUCAST (2023)

>4

0.5

CONCLUSIONS


SXT (n=125)

- FDC showed potent *in vitro* activity against *S. maltophilia* clinical isolates collected in the US and Europe from 2020-2023, including clinical isolates non-susceptible to LVX, SXT, or MIN.
- FDC should be considered as a therapeutic option to treat infections caused by *S. maltophilia*.

< Conflict of interest statement >

Funding: This research was sponsored by Shionogi & Co., Ltd.

Conflict of interest: MO, HY, BD, SN, CL, MT, and YY are employees of Shionogi & Co., Ltd. and its affiliates.



≤0.12 - >4

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from IDWeek 2024 and the authors of the poster.